Annual Statement of Changes in Beneficial Ownership (5)
14 Febbraio 2022 - 11:14PM
Edgar (US Regulatory)
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ]
Form 3 Holdings Reported
[X]
Form 4 Transactions Reported
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0362
Estimated average burden hours per response...
1.0
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Jakobovits Aya | 2. Issuer Name and Ticker or Trading SymbolAdicet Bio, Inc. [ACET] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6 | 3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) 12/31/2021 |
(Street)
BOSTON, MA 02116
(City)
(State)
(Zip)
| 4. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form Filed by One Reporting Person
___ Form Filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
Amount | (A) or (D) | Price |
Common Stock | 12/22/2021 | | S4 (1) | 7000 | D | $16.0162 (2) | 332552 | I | See Footnote (3) |
Common Stock | 12/22/2021 | | S4 (1) | 7000 | D | $16.0286 (4) | 332553 | I | See Footnote (5) |
Common Stock | 12/23/2021 | | G5 (6) | 109488 | D | $0.00 | 0 | I | See Footnote (7) |
Common Stock | 12/23/2021 | | G5 (6) | 29905 | A | $0.00 | 138076 | I | See Footnote (8) |
Common Stock | 12/23/2021 | | G5 (6) | 39791 | A | $0.00 | 372343 | I | See Footnote (3) |
Common Stock | 12/23/2021 | | G5 (6) | 39792 | A | $0.00 | 372345 | I | See Footnote (5) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (MM/DD/YYYY) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
(A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | These sales were effected pursuant to Rule 10b5-1 trading plans previously adopted by the Reporting Person. |
(2) | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.46 to $16.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
(3) | Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary. |
(4) | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.47 to $16.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
(5) | Shares held in a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary. |
(6) | Represents a gift of Common Stock made on December 23, 2021. |
(7) | Shares transferred from a grantor retained annuity trust ("GRAT") of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits the sole annuitant and current beneficiary. Following this transaction, this GRAT was terminated. |
(8) | Shares held in a revocable trust of which Dr. Jakobovits and her spouse are co-trustees. |
Remarks: The Form 4s filed by Dr. Jakobovits on May 14, 2021, May 20, 2021 and June 17, 2021 (the "Prior Filings") incorrectly allocated the shares between trusts over which Dr. Jakobovits has beneficial ownership. The aggregate number of shares beneficially owned as reported in Column 5 of Table I on each of the Prior Filings was correct. Following the transactions reported on this Form 5, the shares over which Dr. Jakobovits has beneficial ownership are held in three trusts: (i) a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' daughter is the beneficiary, (ii) a trust of which Dr. Jakobovits' spouse is the trustee and Dr. Jakobovits' son is the beneficiary, and (ii) a revocable trust of which Dr. Jakobovits and her spouse are co-trustees. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Jakobovits Aya C/O ADICET BIO, INC. 200 CLARENDON STREET, FLOOR 6 BOSTON, MA 02116 | X |
|
|
|
Signatures
|
/s/ Nick Harvey, Attorney-in-Fact for Aya Jakobovits | | 2/14/2022 |
**Signature of Reporting Person | Date |
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Ott 2023 a Ott 2024